Intranasal delivery of vaccines against HIV

Bibliography

• PEPPOLONI S, RUGGIERO P, CONTORNI M et al.: Mutants of the Escherichia coli heat-labile enterotoxin as safe and strong adjuvants for intranasal delivery of vaccines. Expert Rev. Vaccines (2003) 2(2):285-293.
   PubMedGoogle Scholar
• MESTECKY J, MOLDOVEANU Z, RUSSELL MW: Immunologic uniqueness of the genital tract: challenge for vaccine development. Am. J. Reprod. Immunol. (2005) 53(5):208-214.
   PubMed Web of Science ®Google Scholar
• MCGHEE JR, LAMM ME, STROBER W: Mucosal immune responses. In: Mucosal Immunology. PL Ogra, J Mestecky, ME Lamm, W Strober, J Bienenstock, JR McGhee (Eds), Academic Press, San Diego, CA, USA (1999):485-506.
   Google Scholar
• GALLICHAN WS, ROSENTHAL KL: Specific secretory immune responses in the female genital tract following intranasal immunization with a recombinant adenovirus expressing glycoprotein B of herpes simplex virus. Vaccine (1995) 13(16):1589-1595.
   PubMed Web of Science ®Google Scholar
• STAATS HF, MONTGOMERY SP, PALKER TJ: Intranasal immunization is superior to vaginal, gastric, or rectal immunization for the induction of systemic and mucosal anti-HIV antibody responses. AIDS Res. Hum. Retroviruses (1997) 13(11):945-952.
   PubMed Web of Science ®Google Scholar
• WU HY, ABDU S, STINSON D, RUSSELL MW: Generation of female genital tract antibody responses by local or central (common) mucosal immunization. Infect. Immun. (2000) 68(10):5539-5545.
   PubMed Web of Science ®Google Scholar
• JOHANSSON EL, RASK C, FREDRIKSSON M et al.: Antibodies and antibody-secreting cells in the female genital tract after vaginal or intranasal immunization with cholera toxin B subunit or conjugates. Infect. Immun. (1998) 66(2):514-520.
   PubMed Web of Science ®Google Scholar
• DI TOMMASO A, SALETTI G, PIZZA M et al.: Induction of antigen-specific antibodies in vaginal secretions by using a nontoxic mutant of heat-labile enterotoxin as a mucosal adjuvant. Infect. Immun. (1996) 64(3):974-979.
   PubMed Web of Science ®Google Scholar
• BERGQUIST C, JOHANSSON EL, LAGERGARD T, HOLMGREN J, RUDIN A: Intranasal vaccination of humans with recombinant cholera toxin B subunit induces systemic and local antibody responses in the upper respiratory tract and the vagina. Infect. Immun. (1997) 65(7):2676-2684.
   PubMed Web of Science ®Google Scholar
• KUPER CF, KOORNSTRA PJ, HAMELEERS DM et al.: The role of nasopharyngeal lymphoid tissue. Immunol. Today (1992) 13(6):219-224.
   PubMedGoogle Scholar
• MOORE KL, DALLEY AF: Clinically Oriented Anatomy. Lippincott Williams & Wilkins, Baltimore, MD, USA (1999):935-935.
   Google Scholar
• FUJIMURA Y: Evidence of M cells as portals of entry for antigens in the nasopharyngeal lymphoid tissue of humans. Virchows Arch. (2000) 436(6):560-566.
   PubMed Web of Science ®Google Scholar
• POPE M: Mucosal dendritic cells and immunodeficiency viruses. J. Infect. Dis. (1999) 179(Suppl. 3):S427-S430.
   PubMed Web of Science ®Google Scholar
• BRANDTZAEG P: Humoral immune response patterns of human mucosae: induction and relation to bacterial respiratory tract infections. J. Infect. Dis. (1992) 165(Suppl. 1):S167-S176.
   PubMed Web of Science ®Google Scholar
• BRANDTZAEG P, BAEKKEVOLD ES, FARSTAD IN et al.: Regional specialization in the mucosal immune system: what happens in the microcompartments? Immunol. Today (1999) 20(3):141-151.
   PubMedGoogle Scholar
• BOYAKA PN, WRIGHT PF, MARINARO M et al.: Human nasopharyngeal-associated lymphoreticular tissues : functional analysis of subepithelial and intraepithelial B and T cells from adenoids and tonsils. Am. J. Pathol. (2000) 157(6):2023-2035.
   PubMed Web of Science ®Google Scholar
• GRAEME-COOK F, BHAN AK, HARRIS NL: Immunohistochemical characterization of intraepithelial and subepithelial mononuclear cells of the upper airways. Am. J. Pathol. (1993) 143(5):1416-1422.
   PubMed Web of Science ®Google Scholar
• YEAMAN GR, WHITE HD, HOWELL A, PRABHALA R, WIRA CR: The mucosal immune system in the human female reproductive tract: potential insights into the heterosexual transmission of HIV. AIDS Res. Hum. Retroviruses (1998) 14(Suppl. 1):S57-S62.
   PubMed Web of Science ®Google Scholar
• JOHANSSON EL, RUDIN A, WASSEN L, HOLMGREN J: Distribution of lymphocytes and adhesion molecules in human cervix and vagina. Immunol. (1999) 96(2):272-277.
   PubMed Web of Science ®Google Scholar
• HU J, GARDNER MB, MILLER CJ: Simian immunodeficiency virus rapidly penetrates the cervicovaginal mucosa after intravaginal inoculation and infects intraepithelial dendritic cells. J. Virol. (2000) 74(13):6087-6095.
   PubMed Web of Science ®Google Scholar
• LOHMAN BL, MILLER CJ, MCCHESNEY MB: Antiviral cytotoxic T lymphocytes in vaginal mucosa of simian immunodeficiency virus-infected rhesus macaques. J.Immunol. (1995) 155(12):5855-5860.
   PubMed Web of Science ®Google Scholar
• MCCHESNEY MB, COLLINS JR, MILLER CJ: Mucosal phenotype of antiviral cytotoxic T lymphocytes in the vaginal mucosa of SIV-infected rhesus macaques. AIDS Res. Hum. Retroviruses (1998) 14(Suppl. 1):S63-S66.
   Google Scholar
• CHALLACOMBE SJ, RAHMAN D, O’HAGAN DT: Salivary, gut, vaginal and nasal antibody responses after oral immunization with biodegradable microparticles. Vaccine (1997) 15(2):169-175.
   PubMed Web of Science ®Google Scholar
• UGOZZOLI M, O’HAGAN DT, OTT GS: Intranasal immunization of mice with herpes simplex virus type 2 recombinant gD2: the effect of adjuvants on mucosal and serum antibody responses. Immunol. (1998) 93(4):563-571.
   PubMed Web of Science ®Google Scholar
• PARR MB, PARR EL: Immunohistochemical localization of immunoglobulins A, G and M in the mouse female genital tract. J. Reprod. Fertil. (1985) 74(2):361-370.
   PubMedGoogle Scholar
• THAPARR MA, PARR EL, BOZZOLA JJ, PARR MB: Secretory immune responses in the mouse vagina after parenteral or intravaginal immunization with an immunostimulating complex (ISCOM). Vaccine (1991) 9(2):129-133.
   PubMed Web of Science ®Google Scholar
• O’HAGAN DT, RAFFERTY D, MCKEATING JA, ILLUM L: Vaginal immunization of rats with a synthetic peptide from human immunodeficiency virus envelope glycoprotein. J. Gen. Virol. (1992) 73(Pt 8):2141-2145.
   PubMed Web of Science ®Google Scholar
• O’HAGAN DT, RAFFERTY D, WHARTON S, ILLUM L: Intravaginal immunization in sheep using a bioadhesive microsphere antigen delivery system. Vaccine (1993) 11(6):660-664.
   PubMed Web of Science ®Google Scholar
• VAJDY M, GARDNER J, NEIDLEMAN J et al.: Human immunodeficiency virus type 1 Gag-specific vaginal immunity and protection after local immunizations with sindbis virus-based replicon particles. J. Infect. Dis. (2001) 184(12):1613-1616.
   PubMed Web of Science ®Google Scholar
• GUPTA S, JANANI R, BIN Q et al.: Characterization of HIV-gag-specific IFNγ-expressing cells following protective mucosal immunization with alphavirus replicon particles. J. Virol. (2005) 79(11):7135-7145.
   PubMed Web of Science ®Google Scholar
• WIRA CR, RICHARDSON J, PRABHALA R: Endocrine regulation of mucosal immunity: effect of sex hormones and cytokines on the afferent and efferent arms of the immune system in the female reproductive tract. In: Handbook of Mucosal Immunology. PL Ogra, J Mestecky, ME Lamm, JR McGhee, W Strober, J Bienenstock. (Eds), Academic Press, San Diego, CA, USA (1994):705-718.
   Google Scholar
• STAATS HF, NICHOLS WG, PALKER TJ et al.: Mucosal immunity to HIV-1: systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide T1SP10 MN(A). J. Immunol. (1996) 157(1):462-472.
   PubMed Web of Science ®Google Scholar
• HOLMGREN J, ADAMSSON J, ANJUERE F et al.: Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA. Immunol. Lett. (2005) 97(2):181-188.
   PubMed Web of Science ®Google Scholar
• NEIDLEMAN JA, VAJDY M, UGOZZOLI M, OTT G, O’HAGAN D: Genetically detoxified mutants of heat-labile enterotoxin from Escherichia coli are effective adjuvants for induction of cytotoxic T cell responses against HIV-1 gag-p55. Immunology (2000) 101(1):154-160.
   PubMed Web of Science ®Google Scholar
• MORRIS CB, CHENG E, THANAWASTIEN A, CARDENAS-FREYTAG L, CLEMENTS JD: Effectiveness of intranasal immunization with HIV-gp160 and an HIV-1 env CTL epitope peptide (E7) in combination with the mucosal adjuvant LT(R192G). Vaccine (2000) 18(18):1944-1951.
   PubMed Web of Science ®Google Scholar
• MANOCHA M, PAL PC, CHITRALEKHA KT et al.: Enhanced mucosal and systemic immune response with intranasal immunization of mice with HIV peptides entrapped in PLG microparticles in combination with Ulex Europaeus-I lectin as M cell target. Vaccine (2005) 23(48-49):5599-5617.
   PubMed Web of Science ®Google Scholar
• HORNER AA, DATTA SK, TAKABAYASHI K et al.: Immunostimulatory DNA-based vaccines elicit multifaceted immune responses against HIV at systemic and mucosal sites. J. Immunol. (2001) 167(3):1584-1591.
   PubMed Web of Science ®Google Scholar
• BRADNEY CP, SEMPOWSKI GD, LIAO HX, HAYNES BF, STAATS HF: Cytokines as adjuvants for the induction of anti-human immunodeficiency virus peptide immunoglobulin G (IgG) and IgA antibodies in serum and mucosal secretions after nasal immunization. J. Virol. (2002) 76(2):517-524.
   PubMed Web of Science ®Google Scholar
• ALBU DI, JONES-TROWER A, WORON AM et al.: Intranasal vaccination using interleukin-12 and cholera toxin subunit B as adjuvants to enhance mucosal and systemic immunity to human immunodeficiency virus type 1 glycoproteins. J. Virol. (2003) 77(10):5589-5597.
   PubMed Web of Science ®Google Scholar
• BORSUTZKY S, FIORELLI V, EBENSEN T et al.: Efficient mucosal delivery of the HIV-1 Tat protein using the synthetic lipopeptide MALP-2 as adjuvant. Eur. J. Immunol. (2003) 33(6):1548-1556.
   PubMed Web of Science ®Google Scholar
• SAKAUE G, HIROI T, NAKAGAWA Y et al.: HIV mucosal vaccine: nasal immunization with gp160-encapsulated hemagglutinating virus of Japan-liposome induces antigen-specific CTLs and neutralizing antibody responses. J. Immunol. (2003) 170(1):495-502.
   PubMed Web of Science ®Google Scholar
• MANTIS NJ, KOZLOWSKI PA, MIELCARZ DW, WEISSENHORN W, NEUTRA MR: Immunization of mice with recombinant gp41 in a systemic prime/mucosal boost protocol induces HIV-1-specific serum IgG and secretory IgA antibodies. Vaccine (2001) 19(28-29):3990-4001.
   PubMed Web of Science ®Google Scholar
• MATOBA N, MAGERUS A, GEYER BC et al.: A mucosally targeted subunit vaccine candidate eliciting HIV-1 transcytosis-blocking Abs. Proc. Natl. Acad. Sci. USA (2004) 101(37):13584-13589.
   PubMed Web of Science ®Google Scholar
• KLAVINSKIS LS, GAO L, BARNFIELD C, LEHNER T, PARKER S: Mucosal immunization with DNA-liposome complexes. Vaccine (1997) 15(8):818-820.
   PubMed Web of Science ®Google Scholar
• SASAKI S, HAMAJIMA K, FUKUSHIMA J et al.: Comparison of intranasal and intramuscular immunization against human immunodeficiency virus type 1 with a DNA-monophosphoryl lipid A adjuvant vaccine. Infect. Immun. (1998) 66(2):823-826.
   PubMed Web of Science ®Google Scholar
• HAMAJIMA K, SASAKI S, FUKUSHIMA J et al.: Intranasal administration of HIV-DNA vaccine formulated with a polymer, carboxymethylcellulose, augments mucosal antibody production and cell-mediated immune response. Clin. Immunol. Immunopathol. (1998) 88(2):205-210.
   PubMedGoogle Scholar
• XIN KQ, LU Y, HAMAJIMA K et al.: Immunization of RANTES expression plasmid with a DNA vaccine enhances HIV-1-specific immunity. Clin. Immunol. (1999) 92(1):90-96.
   PubMed Web of Science ®Google Scholar
• SINGH M, BRIONES M, OTT G, O’HAGAN D: Cationic microparticles: a potent delivery system for DNA vaccines. Proc. Natl. Acad. Sci. USA (2000) 97(2):811-816.
   PubMed Web of Science ®Google Scholar
• SINGH M, VAJDY M, GARDNER J, BRIONES M, O’HAGAN D: Mucosal immunization with HIV-1 gag DNA on cationic microparticles prolongs gene expression and enhances local and systemic immunity. Vaccine (2001) 20(3-4):594-602.
   PubMed Web of Science ®Google Scholar
• WANG X, HONE DM, HADDAD A, SHATA MT, PASCUAL DW: M cell DNA vaccination for CTL immunity to HIV. J. Immunol. (2003) 171(9):4717-4725.
   PubMed Web of Science ®Google Scholar
• HAMAJIMA K, KOJIMA Y, MATSUI K et al.: Chitin Micro-Particles (CMP): a useful adjuvant for inducing viral specific immunity when delivered intranasally with an HIV-DNA vaccine. Viral Immunol. (2003) 16(4):541-547.
   PubMed Web of Science ®Google Scholar
• LOCHER CP, WITT SA, ASHLOCK BM, LEVY JA: Evaluation of genetic immunization adjuvants to improve the effectiveness of a human immunodeficiency virus type 2 (HIV-2) envelope DNA vaccine. DNA Cell Biol. (2004) 23(2):107-110.
   PubMed Web of Science ®Google Scholar
• CANNON G, WEISSMAN D: RNA based vaccines. DNA Cell Biol. (2002) 21(12):953-961.
   PubMed Web of Science ®Google Scholar
• MARTINON F, KRISHNAN S, LENZEN G et al.: Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA. Eur. J. Immunol. (1993) 23(7):1719-1722.
   PubMed Web of Science ®Google Scholar
• POLO JM, GARDNER JP, JI Y et al.: Alphavirus DNA and particle replicons for vaccines and gene therapy. Dev. Biol. (Basel) (2000) 104:181-185.
   PubMedGoogle Scholar
• LI HO, ZHU YF, ASAKAWA M et al.: A cytoplasmic RNA vector derived from nontransmissible Sendai virus with efficient gene transfer and expression. J. Virol. (2000) 74(14):6564-6569.
   PubMed Web of Science ®Google Scholar
• SCHOEN C, KOLB-MAURER A, GEGINAT G et al.: Bacterial delivery of functional messenger RNA to mammalian cells. Cell Microbiol. (2005) 7(5):709-724.
   PubMed Web of Science ®Google Scholar
• MICHIELS A, TUYAERTS S, BONEHILL A et al.: Electroporation of immature and mature dendritic cells: implications for dendritic cell-based vaccines. Gene Ther. (2005) 12(9):772-782.
   PubMed Web of Science ®Google Scholar
• YOSHII K, HAYASAKA D, GOTO A et al.: Packaging the replicon RNA of the Far-Eastern subtype of tick-borne encephalitis virus into single-round infectious particles: development of a heterologous gene delivery system. Vaccine (2005) 23(30):3946-3956.
   PubMed Web of Science ®Google Scholar
• SHINYA K, FUJII Y, ITO H et al.: Characterization of a neuraminidase-deficient influenza a virus as a potential gene delivery vector and a live vaccine. J. Virol. (2004) 78(6):3083-3088.
   PubMed Web of Science ®Google Scholar
• AHLQUIST P, SCHWARTZ M, CHEN J et al.: Viral and host determinants of RNA virus vector replication and expression. Vaccine (2005) 23(15):1784-1787.
   PubMed Web of Science ®Google Scholar
• RAYNER JO, DRYGA SA, KAMRUD KI: Alphavirus vectors and vaccination. Rev. Med. Virol. (2002) 12(5):279-296.
   PubMed Web of Science ®Google Scholar
• SCHLESINGER S: Alphavirus vectors: development and potential therapeutic applications. Expert Opin. Biol. Ther. (2001) 1(2):177-191.
   PubMed Web of Science ®Google Scholar
• SCHLESINGER S, DUBENSKY TW: Alphavirus vectors for gene expression and vaccines. Curr. Opin. Biotechnol. (1999) 10(5):434-439.
   PubMed Web of Science ®Google Scholar
• LEITNER WW, HWANG LN, DEVEER MJ et al.: Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways. Nat. Med. (2003) 9(1):33-39.
   PubMed Web of Science ®Google Scholar
• CALEY IJ, BETTS MR, IRLBECK DM et al.: Humoral, mucosal, and cellular immunity in response to a human immunodeficiency virus type 1 immunogen expressed by a Venezuelan equine encephalitis virus vaccine vector. J. Virol. (1997) 71(4):3031-3038.
   PubMed Web of Science ®Google Scholar
• BERGLUND P, QUESADA-ROLANDER M, PUTKONEN P et al.: Outcome of immunization of cynomolgus monkeys with recombinant Semliki Forest virus encoding human immunodeficiency virus type 1 envelope protein and challenge with a high dose of SHIV-4 virus. AIDS Res. Hum. Retroviruses (1997) 13(17):1487-1495.
   PubMed Web of Science ®Google Scholar
• BRAND D, LEMIALE F, TURBICA I et al.: Comparative analysis of humoral immune responses to HIV type 1 envelope glycoproteins in mice immunized with a DNA vaccine, recombinant Semliki Forest virus RNA, or recombinant Semliki Forest virus particles. AIDS Res. Hum. Retroviruses (1998) 14(15):1369-1377.
   PubMed Web of Science ®Google Scholar
• PAN CH, VALSAMAKIS A, COLELLA T et al.: Inaugural article: modulation of disease, T cell responses, and measles virus clearance in monkeys vaccinated with H-encoding alphavirus replicon particles. Proc. Natl. Acad. Sci. USA (2005) 102(33):11581-11588.
   Google Scholar
• BELYAKOV IM, MOSS B, STROBER W, BERZOFSKY JA: Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity. Proc. Natl. Acad. Sci. USA (1999) 96(8):4512-4517.
   PubMed Web of Science ®Google Scholar
• HOFMANN-LEHMANN R, VLASAK J, WILLIAMS AL et al.: Live attenuated, nef-deleted SIV is pathogenic in most adult macaques after prolonged observation. AIDS (2003) 17(2):157-166.
   PubMed Web of Science ®Google Scholar
• RUPRECHT RM: Live attenuated AIDS viruses as vaccines: promise or peril? Immunol. Rev. (1999) 170:135-149.
   PubMed Web of Science ®Google Scholar
• BABA TW, LISKA V, KHIMANI AH et al.: Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques. Nat. Med. (1999) 5(2):194-203.
   PubMed Web of Science ®Google Scholar
• BABA TW, JEONG YS, PENNICK D et al.: Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. Science (1995) 267(5205):1820-1825.
   PubMed Web of Science ®Google Scholar
• WYAND MS, MANSON K, MONTEFIORI DC et al.: Protection by live, attenuated simian immunodeficiency virus against heterologous challenge. J. Virol. (1999) 73(10):8356-8363.
   PubMed Web of Science ®Google Scholar
• JOHNSON RP, LIFSON JD, CZAJAK SC et al.: Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge: inverse relationship of degree of protection with level of attenuation. J. Virol. (1999) 73(6):4952-4961.
   PubMed Web of Science ®Google Scholar
• GHERARDI MM, NAJERA JL, PEREZ-JIMENEZ E et al.: Prime-boost immunization schedules based on influenza virus and vaccinia virus vectors potentiate cellular immune responses against human immunodeficiency virus Env protein systemically and in the genitorectal draining lymph nodes. J. Virol. (2003) 77(12):7048-7057.
   PubMed Web of Science ®Google Scholar
• GHERARDI MM, PEREZ-JIMENEZ E, NAJERA JL, ESTEBAN M: Induction of HIV immunity in the genital tract after intranasal delivery of a MVA vector: enhanced immunogenicity after DNA prime-modified vaccinia virus Ankara boost immunization schedule. J. Immunol. (2004) 172(10):6209-6220.
   PubMed Web of Science ®Google Scholar
• STEVCEVA L, ALVAREZ X, LACKNER AA et al.: Both mucosal and systemic routes of immunization with the live, attenuated NYVAC/simian immunodeficiency virus SIV(gpe) recombinant vaccine result in gag-specific CD8(+) T-cell responses in mucosal tissues of macaques. J. Virol. (2002) 76(22):11659-11676.
   PubMed Web of Science ®Google Scholar
• BERTLEY FM, KOZLOWSKI PA, WANG SW et al.: Control of simian/human immunodeficiency virus viremia and disease progression after IL-2-augmented DNA-modified vaccinia virus Ankara nasal vaccination in nonhuman primates. J. Immunol. (2004) 172(6):3745-3757.
   PubMed Web of Science ®Google Scholar
• AMARA RR, VILLINGER F, ALTMAN JD et al.: Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science (2001) 292(5514):69-74.
   Google Scholar
• VOGEL TU, REYNOLDS MR, FULLER DH et al.: Multispecific vaccine-induced mucosal cytotoxic T lymphocytes reduce acute-phase viral replication but fail in long-term control of simian immunodeficiency virus SIVmac239. J. Virol. (2003) 77(24):13348-13360.
   PubMed Web of Science ®Google Scholar
• SANTRA S, BAROUCH DH, KORIOTH-SCHMITZ B et al.: Recombinant poxvirus boosting of DNA-primed rhesus monkeys augments peak but not memory T lymphocyte responses. Proc. Natl. Acad. Sci. USA (2004) 101(30):11088-11093.
   PubMed Web of Science ®Google Scholar
• WANG SW, BERTLEY FM, KOZLOWSKI PA et al.: An SHIV DNA/MVA rectal vaccination in macaques provides systemic and mucosal virus-specific responses and protection against AIDS. AIDS Res. Hum. Retroviruses (2004) 20(8):846-859.
   PubMed Web of Science ®Google Scholar
• BAROUCH DH, MCKAY PF, SUMIDA SM et al.: Plasmid chemokines and colony-stimulating factors enhance the immunogenicity of DNA priming-viral vector boosting human immunodeficiency virus type 1 vaccines. J. Virol. (2003) 77(16):8729-8735.
   PubMed Web of Science ®Google Scholar
• PEACOCK JW, NORDONE SK, JACKSON SS et al.: Gender differences in human immunodeficiency virus type 1-specific CD8 responses in the reproductive tract and colon following nasal peptide priming and modified vaccinia virus Ankara boosting. J. Virol. (2004) 78(23):13163-13172.
   PubMed Web of Science ®Google Scholar
• EDGHILL-SMITH Y, BRAY M, WHITEHOUSE CA et al.: Smallpox vaccine does not protect macaques with AIDS from a lethal monkeypox virus challenge. J. Infect. Dis. (2005) 191(3):372-381.
   PubMed Web of Science ®Google Scholar
• CHAN KS, VERARDI PH, LEGRAND FA, YILMA TD: Nef from pathogenic simian immunodeficiency virus is a negative factor for vaccinia virus. Proc. Natl. Acad. Sci. USA (2005) 102(24):8734-8739.
   PubMed Web of Science ®Google Scholar
• HARRER E, BAUERLE M, FERSTL B et al.: Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption. Antivir. Ther. (2005) 10(2):285-300.
   PubMed Web of Science ®Google Scholar
• FRANCHINI G, GURUNATHAN S, BAGLYOS L, PLOTKIN S, TARTAGLIA J: Poxvirus-based vaccine candidates for HIV: two decades of experience with special emphasis on canarypox vectors. Expert Rev. Vaccines (2004) 3(4 Suppl.):S75-S88.
   PubMed Web of Science ®Google Scholar
• IM EJ, HANKE T: MVA as a vector for vaccines against HIV-1. Expert Rev. Vaccines (2004) 3(4 Suppl.):S89-S97.
   Google Scholar
• AMARA RR, ROBINSON HL: A new generation of HIV vaccines. Trends Mol. Med. (2002) 8(10):489-495.
   PubMed Web of Science ®Google Scholar
• ROSE NF, MARX PA, LUCKAY A et al.: An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell (2001) 106(5):539-549.
   PubMed Web of Science ®Google Scholar
• EGAN MA, CHONG SY, ROSE NF et al.: Immunogenicity of attenuated vesicular stomatitis virus vectors expressing HIV type 1 env and SIV gag proteins: comparison of intranasal and intramuscular vaccination routes. AIDS Res. Hum. Retroviruses (2004) 20(9):989-1004.
   PubMed Web of Science ®Google Scholar
• HAGLUND K, LEINER I, KERKSIEK K et al.: High-level primary CD8(+) T-cell response to human immunodeficiency virus type 1 gag and env generated by vaccination with recombinant vesicular stomatitis viruses. J. Virol. (2002) 76(6):2730-2738.
   PubMed Web of Science ®Google Scholar
• SCHMITT B: Vesicular stomatitis. Vet. Clin. North Am. Food Anim. Pract. (2002) 18(3):453-459, vii-viii.
   PubMed Web of Science ®Google Scholar
• LETCHWORTH GJ, RODRIGUEZ LL, DEL CBARRERA J: Vesicular stomatitis. Vet. J. (1999) 157(3):239-260.
   PubMed Web of Science ®Google Scholar
• KOVACS GM, HARRACH B, ZAKHARTCHOUK AN, DAVISON AJ: Complete genome sequence of simian adenovirus 1: an Old World monkey adenovirus with two fiber genes. J. Gen. Virol. (2005) 86(Pt 6):1681-1686.
   Google Scholar
• CHOI EH, KIM HS, EUN BW et al.: Adenovirus type 7 peptide diversity during outbreak, Korea, 1995-2000. Emerg. Infect. Dis. (2005) 11(5):649-654.
   PubMed Web of Science ®Google Scholar
• GRAY GC, SETTERQUIST SF, JIRSA SJ, DESJARDIN LE, ERDMAN DD: Emergent strain of human adenovirus endemic in Iowa. Emerg. Infect. Dis. (2005) 11(1):127-128.
   PubMed Web of Science ®Google Scholar
• CHEN HL, CHIOU SS, HSIAO HP et al.: Respiratory adenoviral infections in children: a study of hospitalized cases in southern Taiwan in 2001-2002. J. Trop. Pediatr. (2004) 50(5):279-284.
   PubMed Web of Science ®Google Scholar
• LICHTENSTEIN DL, WOLD WS: Experimental infections of humans with wild-type adenoviruses and with replication-competent adenovirus vectors: replication, safety, and transmission. Cancer Gene Ther. (2004) 11(12):819-829.
   PubMed Web of Science ®Google Scholar
• ROELVINK PW, LIZONOVA A, LEE JG et al.: The coxsackievirus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F. J. Virol. (1998) 72(10):7909-7915.
   PubMed Web of Science ®Google Scholar
• LEMIALE F, KONG WP, AKYUREK LM et al.: Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system. J. Virol. (2003) 77(18):10078-10087.
   PubMed Web of Science ®Google Scholar
• THOMAS CE, EHRHARDT A, KAY MA: Progress and problems with the use of viral vectors for gene therapy. Nat. Rev. Genet. (2003) 4(5):346-358.
   PubMed Web of Science ®Google Scholar
• NATUK RJ, CHANDA PK, LUBECK MD et al.: Adenovirus-human immunodeficiency virus (HIV) envelope recombinant vaccines elicit high-titered HIV-neutralizing antibodies in the dog model. Proc. Natl. Acad. Sci. USA (1992) 89(16):7777-7781.
   PubMed Web of Science ®Google Scholar
• NATUK RJ, LUBECK MD, CHANDA PK et al.: Immunogenicity of recombinant human adenovirus-human immunodeficiency virus vaccines in chimpanzees. AIDS Res. Hum. Retroviruses (1993) 9(5):395-404.
   PubMed Web of Science ®Google Scholar
• LUBECK MD, NATUK RJ, CHENGALVALA M et al.: Immunogenicity of recombinant adenovirus-human immunodeficiency virus vaccines in chimpanzees following intranasal administration. AIDS Res. Hum. Retroviruses (1994) 10(11):1443-1449.
   PubMed Web of Science ®Google Scholar
• BAROUCH DH, NABEL GJ: Adenovirus vector-based vaccines for human immunodeficiency virus type 1. Hum. Gene Ther. (2005) 16(2):149-156.
   PubMed Web of Science ®Google Scholar
• SHIVER JW, EMINI EA: Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Ann. Rev. Med. (2004) 55:355-372.
   PubMed Web of Science ®Google Scholar
• SANTRA S, SEAMAN MS, XU L et al.: Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates. J. Virol. (2005) 79(10):6516-6522.
   PubMed Web of Science ®Google Scholar
• MASCOLA JR, SAMBOR A, BEAUDRY K et al.: Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins. J. Virol. (2005) 79(2):771-779.
   PubMed Web of Science ®Google Scholar
• GOMEZ-ROMAN VR, PATTERSON LJ, VENZON D et al.: Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251. J. Immunol. (2005) 174(4):2185-2189.
   PubMed Web of Science ®Google Scholar
• CASIMIRO DR, BETT AJ, FU TM et al.: Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectors. J. Virol. (2004) 78(20):11434-11438.
   PubMed Web of Science ®Google Scholar
• GOMEZ-ROMAN VR, ROBERT-GUROFF M: Adenoviruses as vectors for HIV vaccines. AIDS Rev. (2003) 5(3):178-185.
   PubMedGoogle Scholar
• FERKO B, STASAKOVA J, SEREINIG S et al.: Hyperattenuated recombinant influenza A virus nonstructural-protein-encoding vectors induce human immunodeficiency virus type 1 Nef-specific systemic and mucosal immune responses in mice. J. Virol. (2001) 75(19):8899-8908.
   PubMed Web of Science ®Google Scholar
• FERKO B, KATINGER D, GRASSAUER A et al.: Chimeric influenza virus replicating predominantly in the murine upper respiratory tract induces local immune responses against human immunodeficiency virus type 1 in the genital tract. J. Infect. Dis. (1998) 178(5):1359-1368.
   PubMed Web of Science ®Google Scholar
• MUSTER T, FERKO B, KLIMA A et al.: Mucosal model of immunization against human immunodeficiency virus type 1 with a chimeric influenza virus. J. Virol. (1995) 69(11):6678-6686.
   PubMed Web of Science ®Google Scholar
• KANG SM, GUO L, YAO Q, SKOUNTZOU I, COMPANS RW: Intranasal immunization with inactivated influenza virus enhances immune responses to coadministered simian-human immunodeficiency virus-like particle antigens. J. Virol. (2004) 78(18):9624-9632.
   PubMed Web of Science ®Google Scholar
• CROTTY S, ANDINO R: Poliovirus vaccine strains as mucosal vaccine vectors and their potential use to develop an AIDS vaccine. Adv. Drug Deliv. Rev. (2004) 56(6):835-852.
   PubMed Web of Science ®Google Scholar
• TAN GS, MCKENNA PM, KOSER ML et al.: Strong cellular and humoral anti-HIV Env immune responses induced by a heterologous rhabdoviral prime-boost approach. Virology (2005) 331(1):82-93.
   PubMed Web of Science ®Google Scholar
• DURRANI Z, MCINERNEY TL, MCLAIN L et al.: Intranasal immunization with a plant virus expressing a peptide from HIV-1 gp41 stimulates better mucosal and systemic HIV-1-specific IgA and IgG than oral immunization. J. Immunol. Methods (1998) 220(1-2):93-103.
   PubMed Web of Science ®Google Scholar
• AKAGI T, KAWAMURA M, UENO M et al.: Mucosal immunization with inactivated HIV-1-capturing nanospheres induces a significant HIV-1-specific vaginal antibody response in mice. J. Med. Virol. (2003) 69(2):163-172.
   PubMed Web of Science ®Google Scholar
• MIYAKE A, AKAGI T, ENOSE Y et al.: Induction of HIV-specific antibody response and protection against vaginal SHIV transmission by intranasal immunization with inactivated SHIV-capturing nanospheres in macaques. J. Med. Virol. (2004) 73(3):368-377.
   PubMed Web of Science ®Google Scholar
• DUMAIS N, PATRICK A, MOSS RB, DAVIS HL, ROSENTHAL KL: Mucosal immunization with inactivated human immunodeficiency virus plus CpG oligodeoxynucleotides induces genital immune responses and protection against intravaginal challenge. J. Infect. Dis. (2002) 186(8):1098-1105.
   PubMed Web of Science ®Google Scholar
• JIANG JQ, PATRICK A, MOSS RB, ROSENTHAL KL: CD8+ T-cell-mediated cross-clade protection in the genital tract following intranasal immunization with inactivated human immunodeficiency virus antigen plus CpG oligodeoxynucleotides. J. Virol. (2005) 79(1):393-400.
   PubMed Web of Science ®Google Scholar
• KAWAHARA M, MATSUO K, NAKASONE T et al.: Combined intrarectal/intradermal inoculation of recombinant Mycobacterium bovis bacillus Calmette-Guerin (BCG) induces enhanced immune responses against the inserted HIV-1 V3 antigen. Vaccine (2002) 21(3-4):158-166.
   PubMed Web of Science ®Google Scholar
• GOLDING B, ELLER N, LEVY L et al.: Mucosal immunity in mice immunized with HIV-1 peptide conjugated to Brucella abortus. Vaccine (2002) 20(9-10):1445-1450.
   PubMed Web of Science ®Google Scholar
• DEML L, SPETH C, DIERICH MP, WOLF H, WAGNER R: Recombinant HIV-1 Pr55gag virus-like particles: potent stimulators of innate and acquired immune responses. Mol. Immunol. (2005) 42(2):259-277.
   PubMed Web of Science ®Google Scholar
• YAO Q, BU Z, VZOROV A, YANG C, COMPANS RW: Virus-like particle and DNA-based candidate AIDS vaccines. Vaccine (2003) 21(7-8):638-643.
   PubMed Web of Science ®Google Scholar
• YAO Q: Enhancement of mucosal immune responses by chimeric influenza HA/SHIV virus-like particles. Res. Initiat. Treat. Action (2003) 8(2):20-21.
   PubMedGoogle Scholar
• GRONOWSKI AM, HILBERT DM, SHEEHAN KC, GAROTTA G, SCHREIBER RD: Baculovirus stimulates antiviral effects in mammalian cells. J. Virol. (1999) 73(12):9944-9951.
   PubMed Web of Science ®Google Scholar
• XU F, HONG M, ULMER JB: Immunogenicity of an HIV-1 gag DNA vaccine carried by attenuated Shigella. Vaccine (2003) 21(7-8):644-648.
   PubMed Web of Science ®Google Scholar
• SHATA MT, HONE DM: Vaccination with a Shigella DNA vaccine vector induces antigen-specific CD8(+) T cells and antiviral protective immunity. J. Virol. (2001) 75(20):9665-9670.
   PubMed Web of Science ®Google Scholar
• DEVICO AL, FOUTS TR, SHATA MT et al.: Development of an oral prime-boost strategy to elicit broadly neutralizing antibodies against HIV-1. Vaccine (2002) 20(15):1968-1974.
   PubMed Web of Science ®Google Scholar
• VECINO WH, MORIN PM, AGHA R, JACOBS WR Jr, FENNELLY GJ: Mucosal DNA vaccination with highly attenuated Shigella is superior to attenuated Salmonella and comparable to intramuscular DNA vaccination for T cells against HIV. Immunol. Lett. (2002) 82(3):197-204.
   PubMed Web of Science ®Google Scholar
• MUTSCH M, ZHOU W, RHODES P et al.: Use of the inactivated intranasal influenza vaccine and the risk of Bell’s palsy in Switzerland. N. Engl. J. Med. (2004) 350(9):896-903.
   PubMed Web of Science ®Google Scholar
• COUCH RB: Nasal vaccination, Escherichia coli enterotoxin, and Bell’s palsy. N. Engl. J. Med. (2004) 350(9):860-861.
   PubMed Web of Science ®Google Scholar
• PIERCY J: Bell’s palsy. Br. Med. J. (2005) 330(7504):1374.
   PubMed Web of Science ®Google Scholar
• VAN GINKEL FW, JACKSON RJ, YUKI Y, MCGHEE JR: Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J. Immunol. (2000) 165(9):4778-4782.
   PubMed Web of Science ®Google Scholar
• ERIKSSON AM, SCHON KM, LYCKE NY: The cholera toxin-derived CTA1-DD vaccine adjuvant administered intranasally does not cause inflammation or accumulate in the nervous tissues. J. Immunol. (2004) 173(5):3310-3319.
   PubMed Web of Science ®Google Scholar
• VAN GINKEL FW, JACKSON RJ, YOSHINO N et al.: Enterotoxin-based mucosal adjuvants alter antigen trafficking and induce inflammatory responses in the nasal tract. Infect. Immun. (2005) 73(10):6892-6902.
   PubMed Web of Science ®Google Scholar